Qureight strikes US alliance as new investment round gains traction
Cambridge based imaging analytics trailblazer Qureight has partnered with Greenlight Guru in Indianapolis to leverage the US company’s strength on QMS (Quality Management Software).
The move will enable Qureight to take its groundbreaking, cloud-based platform through ISO13485 accreditation towards a formal CE mark award.
Qureight was founded in 2018 with a vision to transform routine real-world clinical data into structured information suitable for scientific research and the development of AI tools. The company works with highly specialised data sets from complex diseases including lung fibrosis, complex cancers and Covid-19.
By partnering with Biopharma, the company aims to transform the process of drug development from early clinical trials through to drug reimbursement.
Qureight is developing an improved and streamlined version of its platform harnessing the ability of AI and advanced processing tools to gain new insights into these complex diseases.
It says the partnership with Greenlight Guru will create the right foundation to bring the Qureight platform to the market in a rapid and safe way.
Qureight CEO Dr Muhunthan Thillai told Business Weekly the team had grown significantly since it raised £500k seed capital last September. And he revealed that Qureight had recently opened its next investment round and was already getting good traction; he hoped the raise would be completed over the summer.
Dr Thillai said: “Greenlight Guru has world leading expertise in QMS for medical software. By partnering with them we are ensuring that the Qureight platform has the strongest possible base for which to achieve regulatory compliance as we launch our series of AI based tools in complex diseases.
“Qureight has entered into some very exciting territories with Biopharma clients in the UK, Europe and the US. As we move to consolidate these relationships and develop world leading AI solutions to structure complex data, we know that working with Greenlight Guru will place us in a great position for the next stage of our growth.”
Clients using the Qureight platform include the drug companies Takeda, Galapagos and Roche.
Greenlight Guru CEO David DeRam said: “We’re excited to help Dr Thillai and the Qureight team bring their technology to market. We’re optimistic that their AI-based technology will be able to transform the landscape of clinical data and we’re looking forward to equipping them with the perfect quality management system to achieve their goals.”